GENMAB A/S (GMAB) research
GENMAB A/S- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $34.75
- As of
GENMAB A/S (GMAB): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-02.
As of . Source: SEC EDGAR filings for GMAB. Method and limitations.
Share the GMAB intelligence card
See the full GMAB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GMAB on one page. Preview it with sample data, then open it live with a free account.
Preview the GMAB dossierActive signals for GMAB
- highCONSENSUS_BUY
4 tracked funds increased GMAB this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in GMAB
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +243% to GMAB (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2266% to GMAB (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +18658% to GMAB (2026Q2)
FREE, NO ACCOUNT
Every signal on GMAB, as it fires
You are seeing 5 of 18 signals recorded on GMAB since 2026-05-31.
The five above landed across 2 days. The other 13 were recorded on 4 other days. 10 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GMAB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 372303206 · 2026Q2 | $96.6M | 0.13% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 372303206 · 2026Q2 | $96.3M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 372303206 · 2026Q2 | $68M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 372303206 · 2026Q2 | $25M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 372303206 · 2026Q2 | $3.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GMAB
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
GMAB against its peers
GMAB's operating margin of 28.6% ranks in the 66th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | GMAB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.7B USD | 1.9B USD | 82 | 18 |
| Operating margin | 28.6% | 10.5% | 66 | 18 |
| Net margin | 25.9% | 8.4% | 78 | 19 |
| Return on equity | 16.5% | 6.2% | 69 | 20 |
| P / E | n/a | 31.2x | n/a | 10 |
Peers (23): UTHR, INCY, INSM, BNTX, RPRX, ROIV, ALNY, ASND, EXEL, BIIB, NBIX, SMMT, BBIO, HALO, ONC, MDGL, BMRN, RVMD, APGE, KRYS, NUVL, PTGX, KYMR. Left out: IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (GMAB: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GMAB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GMAB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.